Nkarta (NKTX)
Develops NKX019-led CAR NK therapies for B-cell autoimmune diseases.
$2.95
After hours+0.01 (+0.17%)
At close$2.95(+2.26%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 82.90% | 59.37M shares | |
|---|---|---|---|
| 141 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.67% | 1.19M shares | |
| 7 holders · as of Jun 22, 2026 | |||
| Other | ≈ 15.43% | 11.06M shares | |
| remainder | |||
71.62M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
141 holders · 59.37M shares · 28 new positions · 79 increased · 37 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.81M | 15.09% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.30M | 8.80% | +1.79M | Aug 7, 2026 |
| Nea Management Company, LLC | 3.57M | 4.98% | 0 | Aug 14, 2026 |
| Samsara Biocapital, LLC | 3.51M | 4.90% | 0 | Aug 14, 2026 |
| Sr One Capital Management, LP | 3.33M | 4.65% | 0 | Aug 12, 2026 |
| GSK PLC | 3.15M | 4.40% | 0 | Aug 13, 2026 |
| Monaco Asset Management Sam | 2.37M | 3.31% | −148.5K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 2.23M | 3.11% | +215.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 18, 2026 | Paul J. Hastingsdirector, officer: Chief Executive Officer | Sale | 1,776 | $2.71 | 390,247 |
| Jan 15, 2026 | Nadir Mahmoodofficer: President | Sale | 5,649 | $2.07 | 167,727 |
| Jan 15, 2026 | Paul J. Hastingsdirector, officer: Chief Executive Officer | Sale | 26,046 | $2.07 | 390,023 |
House and Senate disclosures
Not reported.